0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Cumulative Epinephrine Dose during Cardiopulmonary Resuscitation and Neurologic Outcome

Wilhelm Behringer, MD; Harald Kittler, MD; Fritz Sterz, MD; Hans Domanovits, MD; Waltraud Schoerkhuber, MD; Michael Holzer, MD; Marcus Mullner, MD; and Anton N. Laggner, MD
[+] Article and Author Information

From University of Vienna Medical School, Vienna, Austria Grant Support: Dr. Behringer is supported by the Ministry of Science, Transport and the Arts (BMWVK), Austria (GZ 5.550/12 −Pr/4/95). Dr. Schoerkhuber is supported by the Fonds zur Foerderung der wissenschaftlichen Forschung (Austrian Science Foundation; P11405-MED). Dr. Holzer is supported by BIOMED2 European Commission, DG XII for Science Research and Development, Directorate Life Science and Technologies, Biomedical and Health Research Division (BMH4-CT96-0667). Requests for Reprints: Fritz Sterz, MD, Vienna General Hospital, University Clinics, Department of Emergency Medicine, Waehringerguertel 18-20/6/D, 1090 Vienna, Austria. Current Author Addresses: Drs. Behringer, Kittler, Sterz, Domanovits, Schoerkhuber, Holzer, Mullner, and Laggner: Vienna General Hospital, Waehringerguertel 18-20, 1090 Vienna, Austria.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1998;129(6):450-456. doi:10.7326/0003-4819-129-6-199809150-00004
Text Size: A A A

Background: Epinephrine is the drug of choice in advanced cardiac life support, but it can have deleterious side effects after restoration of spontaneous circulation.

Objective: To investigate the association between the cumulative epinephrine dose used in advanced cardiac life support and neurologic outcome after cardiac arrest.

Design: Retrospective cohort study.

Setting: University hospital.

Patients: Adults admitted to the emergency department with witnessed, nontraumatic, normothermic ventricular fibrillation cardiac arrest and unsuccessful initial defibrillation.

Measurements: Functional neurologic outcome was regularly assessed by cerebral performance category (CPC) within 6 months after cardiac arrest. A CPC of 1 or 2 was defined as favorable recovery.

Results: Among 178 enrolled patients, the median cumulative epinephrine dose administered was 4 mg (range, 0 to 50 mg). In 151 patients (84%), spontaneous circulation was restored; 63 of these 151 patients (42%) had favorable neurologic recovery. Patients with an unfavorable CPC received a significantly higher cumulative dose of epinephrine than did patients with a favorable CPC (4 mg compared with 1 mg; P < 0.001). This finding persisted after stratification by duration of resuscitation. After possible cofounders were controlled for, the cumulative epinephrine dose remained an independent predictor of unfavorable neurologic outcome.

Conclusions: The results indicate that an increasing cumulative dose of epinephrine administered during resuscitation is independently associated with unfavorable neurologic outcome after ventricular fibrillation cardiac arrest.

Figures

Grahic Jump Location
Figure 1.
Patients who achieved restoration of spontaneous circulation (striped bars) after administration of epinephrine.

White bars represent patients who did not achieve restoration of spontaneous circulation. CPR = cardiopulmonary resuscitation.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Patients who achieved good neurologic outcome after administration of epinephrine (striped bars).

White bars represent patients who did not achieve good neurologic outcome. CPR = cardiopulmonary resuscitation.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Frequencies of favorable and unfavorable neurologic recovery after simultaneous stratification by no-flow duration, low-flow duration, and cumulative epinephrine dose.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
The role of Levosimendan in cardiopulmonary resuscitation. Eur J Pharmacol Published online Jun 24, 2014.;
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)